With a prevalence of 2-4% of the worldwide population, neurodevelopmental disorders (NDDs) comprise a heterogeneous group of disorders associated with neurodevelopmental dysfunction, including intellectual disability (ID), autism spectrum disorder (ASD), Down syndrome (DS) and attention-deficit/hyperactivity disorder (ADHD) among others. However, due to their heterogeneity and overlapping clinical features, NDDs such as ASD are often misdiagnosed, while for others with more distinct symptoms, such as Rett syndrome or DS, the mechanisms underlying their pathogenesis remain elusive. Last year, important steps in the mechanistic understanding of several NDDs have been achieved. New preclinical models demonstrated causality between PAK3 mutations and disorders associated with social deficiencies. ARID1B mutations have been linked to neuroectoderm specification in Coffin-Siris syndrome and DNA damage was established as an important pathologic mechanism in Aicardi-Goutières syndrome. Moreover, alterations in basic molecular processes including translation and histone acet-ylation have been established as major traits in the pathology of X-linked ID and Rett syndrome, revealing new pathogenetic mechanisms. Last year, advances in bioinformatics have begun to shed light on the human re-peatome, a largely unexplored part of our genome, and how alterations in these sequences have a central role in ASD. The role of mitochondria in neuropathology was clarified last year with the discovery of previously unknown vesicles derived from mitochondria with a putative role in DS. An interesting discovery in the field of basic neurodevelopment showed that during postnatal brain development, changes in genome architecture and tran-scriptional dynamics progress independently of sensory experience. Finally, our neurocentric views of NDDs are changing as new players such as astrocytes are revealed to be crucial in neuropathology. The role of astrocytes has been clarified for some pathologies such as ASD and DS, linking well-known genetic mutations to impaired astrocyte function. Abbreviations ADAR1-double-stranded RNA-specific adeno-sine deaminase, AGS-Aicardi-Goutières syndrome, ASD-autism spectrum disorder, ATP-adenosine tri-phosphate, cGAS-GMP-AMP synthase, cKO-conditional knockout, Dip-C-diploid chromatin confor-mation capture, DNA-deoxyribonucleic acid, DS-Down syndrome, EV-extracellular vesicles, GABA-gamma-aminobutyric acid, γH2AX: H2A-histone family member X, hiPSC-human induced pluripo-tent stem cells, Iba1-ionized calcium-binding adaptor molecule 1, ID-intellectual disability, IFN-inter-feron, IP3R2-2 inositol 1,4,5-trisphosphate receptors , LC-MS-liquid chromatography-mass spec-trometry, MeCP2-methyl CpG binding protein 2, NDD-neurodevelopmental disorder, RNA-ribonu-cleic acid, RNASEH2-ribonuclease H2, NMDA-N-methyl-d-aspartic acid or N-methyl-d-aspartate, NOVA1-neuro-oncological ventral antigen 1, PSD95-postsynaptic density 95, RTT-Rett syndrome , RPS4Y1-40S ribosomal protein S4, TADs-topologically associated domains, TRs-tandem-repeat sequence, TREX1-three prime repair exonu-clease 1, tRNA-transfer RNAs, XLID-X-linked intellectual disability.